Back
ESC2025 Premium Access

Efficacy and safety of selexipag based triple combination targeted drug therapy in chinese patients with pulmonary arterial hypertension

Session: Pulmonary arterial hypertension therapy
Topic: Pharmacotherapy
Speaker: Doctor X. Cui (Jinan, CN)
Event: ESC Congress 2025

Congress Presentation

Add to my library

Like

About the speaker

Doctor Xiaopei Cui

Shandong University Qilu Hospital, Jinan (China)
1 follower

4 more presentations in this session

A real-world study on selexipag for pulmonary arterial hypertension: a single-center retrospective study

Speaker: Doctor R. Asano (Suita, JP)

Access
Abstract
Slides
Video
Like
Thumbnail

Safety and efficacy of macitentan and riociguat upfront combination therapy in patients with idiopathic pulmonary arterial hypertension at intermediate risk.

Speaker: Professor M. D'Alto (Naples, IT)

Access
Abstract
Slides
Video
Like
Thumbnail

Could we maintain the initial efficacy of triple sequential combination therapies with selexipag in patients with pulmonary arterial hypertension : Insights from a single-centre study

Speaker: Associate Professor H. Tokgoz (Istanbul, TR)

Access
Abstract
Slides
Video
Like
Thumbnail

Switching sildenafil to riociguat in chronic thromboembolic pulmonary hypertension after balloon pulmonary angioplasty - the S2R study

Speaker: Doctor T. Kam (Shatin, HK)

Access
Abstract
Slides
Video
Like
Thumbnail

Access the full session

Pulmonary arterial hypertension therapy

Speakers: Doctor X. Cui, Doctor R. Asano, Professor M. D'Alto, Associate Professor H. Tokgoz, Doctor T. Kam
Access
Like
Thumbnail

About the event

Image

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

bristol-myers-squibb Explore sponsored resources
novartis Explore sponsored resources